ACADIA Pharmaceuticals Has This Top Analyst Even More Positive on PDP Drug Nuplazid’s Opportunity


ACADIA Pharmaceuticals (NASDAQ:ACAD) just yielded a third quarter outclass that has one of the Street’s top analysts impressed in the upshot. What commercial success does Cowen analyst¬†Ritu Baral¬†spot ahead for the biotech player’s Parkinson’s disease psychosis asset Nuplazid?

Story Continues